鱼精蛋白减少无症状颈动脉内膜剥脱术严重出血并发症而不增加卒中、心梗或死亡风险:大型国家分析
结果显示鱼精蛋白使用率69%且逐年上升,与再手术止血风险降低独立相关(OR 0.5, 95%CI 0.39-0.55; p<.001),未增加心梗、卒中或住院死亡风险。
要点
- 鱼精蛋白使用与颈动脉内膜剥脱术后因出血再手术风险降低独立相关。
- 鱼精蛋白未增加心梗、卒中或住院死亡风险。
- 因出血再手术与心梗、卒中及死亡风险显著增加相关。
核心结论
- 鱼精蛋白减少颈动脉内膜剥脱术时严重出血并发症,且不增加心梗、卒中或死亡风险。
- 基于充足证据支持常规使用鱼精蛋白,并应作为颈动脉内膜剥脱术的质量基准。
研究设计与样本
- 采用多变量逻辑回归及倾向性匹配控制组间差异。
主要发现
- 鱼精蛋白组因出血再手术378例(0.7%),未使用组342例(1.4%)(p < .001)。
- 鱼精蛋白组与未使用组心梗率分别为0.7%与0.8%(p = .023),卒中率分别为1.1%与1.0%(p = .20),住院死亡率均为0.2%(p = 0.70)。
- 多变量分析显示鱼精蛋白使用与因出血再手术风险降低独立相关(OR 0.5, 95%CI 0.39-0.55; p < .001)。
- 因出血再手术与心梗(4.9% vs 0.7%; p < .001)、卒中(7.2% vs 0.9%; p < .001)及死亡(2.4% vs 0.2%; p < .001)风险显著增加相关。
关键数值与推荐
- 鱼精蛋白使用与因出血再手术风险降低独立相关(OR 0.5, 95%CI 0.39-0.55; p < .001)。
- 因出血再手术者心梗风险增加约7倍(4.9% vs 0.7%; p < .001),卒中风险增加约8倍(7.2% vs 0.9%; p < .001),死亡风险增加约13倍(2.4% vs 0.2%; p < .001)。
临床怎么用
- 在择期无症状颈动脉内膜剥脱术中可考虑常规使用鱼精蛋白逆转肝素,以降低因出血再手术风险。
- 鱼精蛋白使用未增加卒中、心梗或死亡风险,支持将其作为颈动脉内膜剥脱术的质量基准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Controversy persists regarding the use of protamine during carotid endarterectomy (CEA), despite real world evidence to support its use. The purpose of this study was to determine the impact of protamine reversal of heparin anticoagulation on the outcome of CEA in the USA. METHODS: A prospective national registry (Society for Vascular Surgery Vascular Quality Initiative) of 72 787 patients undergoing elective asymptomatic CEA by 1879 surgeons from 316 centres in the USA and Canada from 2012 to 2018 was reviewed. Protamine use varied by both surgeon (20% rare use [< 10%], 30% variable use [11%-79%], 50% routine use [> 80% cases]) and geographical region (44% vs. 96%). Temporal trends in protamine use were also determined. End points included post-operative re-operation for bleeding, as well as potential protamine related thrombotic complications, including stroke, death, and myocardial infarction (MI). Predictors of end points were determined by multivariable logistic regression. Propensity matching was additionally used to control for differences between groups. RESULTS: Of the 72 787 patients who underwent CEA, 69% received protamine, while 31% did not. Protamine use increased over time from 60% (2012) to 73% (2018). In total, 378 patients (0.7%) in the protamine treated group underwent re-operation for bleeding vs. 342 patients (1.4%) in the untreated cohort (p < .001). Protamine use did not affect the rate of MI (0.7% vs. 0.8%; p = .023), stroke (1.1% vs. 1.0%; p = .20), or in hospital death (0.2% vs. 0.2%; p = 0.70) between treated and untreated patients, respectively. On multivariable analysis, protamine use was independently associated with reduced risk of re-operation for bleeding (odds ratio 0.5, 95% confidence interval 0.39-0.55; p < .001). Independent of protamine exposure, the consequences of a return to the operating room (RTOR) for bleeding were statistically significant, with a sevenfold increase in MI (RTOR 4.9% vs. no RTOR 0.7%; p < .001), an eightfold increase in stroke (RTOR 7.2% vs. no RTOR 0.9%; p < .001), and a 13 fold increase in death (RTOR 2.4% vs. no RTOR 0.2%; p < .001). CONCLUSION: Protamine reduces serious bleeding complications at the time of CEA without increasing the risk of MI, stroke, or death, in this large North American analysis. Based on this and previous regional work regarding protamine use in CEA, it is believed that there is now sufficient evidence to support its routine use, and it should be considered as a benchmark for quality during CEA.
引用
- Stone DH, Giles KA, Kubilis P, et al. Editor's Choice - Protamine Reduces Serious Bleeding Complications Associated with Carotid Endarterectomy in Asymptomatic Patients without Increasing the Risk of Stroke, Myocardial Infarction, or Death in a Large National Analysis. Eur J Vasc Endovasc Surg. 2020. PMID: 33127243. doi:10.1016/j.ejvs.2020.08.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。